Aplidin
Submitted by Anonymous (not verified) on 10 July 2024 - 15:13
Aplidin
Agenda - Public webinar on pack size submissions: from XEVMPD to product management service (PMS)
Submitted by Anonymous (not verified) on 10 July 2024 - 14:55
Agenda - Public webinar on pack size submissions: from XEVMPD to product management service (PMS)
Human medicines European public assessment report (EPAR): Zevalin, ibritumomab tiuxetan, Date of authorisation: 16/01/2004, Revision: 23, Status: Lapsed
Submitted by Anonymous (not verified) on 10 July 2024 - 13:52
Human medicines European public assessment report (EPAR): Zevalin, ibritumomab tiuxetan, Date of authorisation: 16/01/2004, Revision: 23, Status: Lapsed
Opinion/decision on a Paediatric investigation plan (PIP): onivyde, irinotecan, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0241/2023
Submitted by Anonymous (not verified) on 10 July 2024 - 13:12
Opinion/decision on a Paediatric investigation plan (PIP): onivyde, irinotecan, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0241/2023
EMEA-003408-PIP01-23
Submitted by Anonymous (not verified) on 10 July 2024 - 13:07
EMEA-003408-PIP01-23
EMEA-003398-PIP01-23
Submitted by Anonymous (not verified) on 10 July 2024 - 13:00
EMEA-003398-PIP01-23
EMEA-003391-PIP01-23
Submitted by Anonymous (not verified) on 10 July 2024 - 12:56
EMEA-003391-PIP01-23
EMEA-003387-PIP01-22
Submitted by Anonymous (not verified) on 10 July 2024 - 12:38
EMEA-003387-PIP01-22
EMEA-003384-PIP02-23
Submitted by Anonymous (not verified) on 10 July 2024 - 12:34
EMEA-003384-PIP02-23
EMEA-003383-PIP02-23
Submitted by Anonymous (not verified) on 10 July 2024 - 12:31
EMEA-003383-PIP02-23